Literature DB >> 20843147

Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009.

Mojgan Karimi Zarchi1, Ali Akhavan, Hosien Gholami, Atefeh Dehghani, Masoomeh Naghshi, Fereshteh Mohseni.   

Abstract

BACKGROUND: Although cervical cancer is a preventable disease, its prevalence is increasing in many developing countries. The aim of this study was to evaluate risk factors.
MATERIALS AND METHODS: This cross-sectional study was conducted on 100 cervical cancer cases according to their pathology reports in Yazd city. The patients were referred to 4 gynecological centers. Demographic data (age, age at marriage, number of marriages and spouses, age at first pregnancy, frequency of pregnancies and term labors, positive history of smoking and Pap smear findings were documented by interview, questionnaire and reviewing patients documents. The data were analyzed with SPSS software.
RESULTS: Mean age of the patients was 53.6 years. Mean age of marriage and first pregnancy was 15.2 and 16.6; respectively. Twenty percent (20%) of the cases married more than once and husbands of 38 patients (38%) had another wife too. Frequency of pregnancies and term labors was 7.4 and 6.4 in our patients. Some 17% of the patients had history of smoking; while 53% of them were passive smokers. Also only 2% of our patients have done Pap smear before diagnosis. DISCUSSION: The important risk factors of patients with cervical cancer were as follows: Marriage at young age (15.2%), high mean parity (7.4), low mean age at first pregnancy (16.2 year), smoking, and not doing Pap smear.
CONCLUSION: There is important association between mass screening program with Pap smear and decreasing cervical cancer. Thus we should increase our women knowledge about all of risk-factors of cervical cancer and get them clues about regular pap smears.

Entities:  

Mesh:

Year:  2010        PMID: 20843147

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Evaluation the Presence of SERPINA5 (Exon 3) and FTO rs9939609 Polymorphisms in Papillary Thyroid Cancer Patients.

Authors:  Seyed Mohammad Moshtaghioun; Nasim Fazel-Yazdi; Mohammad Mandegari; Ahmad Shirinzadeh-Dastgiri; Mohammad Vakili; Habib Fazel-Yazdi
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

2.  The Most Common Type of HPV in Women with Atypical Squamous Cell of Undetermined Significance (ASCUS) in Pap Smear in Iran-Yazd.

Authors:  Mojgan Karimi-Zarchi; Afsarosadat Tabatabaie; Alie Dehghani-Firoozabadi; Farima Shamsi; Maleknaz Baghianimoghaddam; Mandana Dargahi; Pouria Yazian; Shahnaz Mojahed
Journal:  Int J Biomed Sci       Date:  2015-12

3.  Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Susceptibility to Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mojgan Karimi-Zarchi; Hajar Abbasi; Atiyeh Javaheri; Amaneh Hadadan; Bahare Meibodi; Razieh Sadat Tabatabaei; Yaser Ghelmani; Hossein Neamatzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

Review 4.  Proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic: A systematic review and meta-analysis.

Authors:  Mohammadali Jafari; Seyed Alireza Dastgheib; Farzad Ferdosian; Hamid Mirjalili; Hossein Aarafi; Mahmood Noorishadkam; Mahta Mazaheri; Hossein Neamatzadeh
Journal:  Hematol Transfus Cell Ther       Date:  2021-12-15

5.  A Meta-Analysis for Association of XRCC3 rs861539, MTHFR rs1801133, IL-6 rs1800795, IL-12B rs3212227, TNF-α rs1800629, and TLR9 rs352140 Polymorphisms with Susceptibility to Cervical Carcinoma.

Authors:  Seyedeh Fatemeh Parsaeian; Fatemeh Asadian; Mojgan Karimi-Zarchi; Sepideh Setayesh; Atiyeh Javaheri; Razieh Sadat Tabatabaie; Seyed Alireza Dastgheib; Hossein Golestanpour; Hossein Neamatzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

6.  Cervical cancer in Iran: integrative insights of epidemiological analysis.

Authors:  Zohre Momenimovahed; Hamid Salehiniya
Journal:  Biomedicine (Taipei)       Date:  2018-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.